GB5005
/ Genechem
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 13, 2021
CAR T-Cell Therapy Shows Consistent Safety and Pharmacokinetics in NHL
(Targeted Oncology)
- "Scott R. Solomon, MD...discusses the adverse events (AEs) and pharmacokinetics of lisocabtagene maraleucel (liso-cel; Breyanzi) in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma (NHL) who had previously received anti-CD19 therapy....Solomon says there was no difference in the expansion kinetics or persistence of these cells, reinforcing what was seen with the efficacy data for this trial."
Video
1 to 1
Of
1
Go to page
1